Lunai Bioworks (NASDAQ:LNAI) Upgraded by Wall Street Zen to Hold Rating

Posted by Linda Flegge on Jan 11th, 2026

Wall Street Zen upgraded shares of Lunai Bioworks (NASDAQ:LNAI – Free Report) from a sell rating to a hold rating in a report issued on Saturday.

Separately, Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Lunai Bioworks in a report on Monday, December 29th. One research analyst has rated the stock with a Sell rating, According to data from MarketBeat, the stock has an average rating of “Sell”.

Read Our Latest Analysis on LNAI

Lunai Bioworks Stock Up 5.5%

NASDAQ LNAI opened at $0.96 on Friday. The firm has a 50-day simple moving average of $1.08. Lunai Bioworks has a 12-month low of $0.81 and a 12-month high of $14.00. The company has a market cap of $22.49 million, a P/E ratio of -13.71 and a beta of 0.40.

Lunai Bioworks (NASDAQ:LNAI – Get Free Report) last released its quarterly earnings results on Friday, November 14th. The company reported $0.13 earnings per share for the quarter.

Institutional Investors Weigh In On Lunai Bioworks

A hedge fund recently bought a new stake in Lunai Bioworks stock. Millennium Management LLC bought a new stake in Lunai Bioworks Inc. (NASDAQ:LNAI – Free Report) during the third quarter, according to the company in its most recent disclosure with the SEC. The firm bought 202,629 shares of the company’s stock, valued at approximately $288,000. Millennium Management LLC owned approximately 0.87% of Lunai Bioworks as of its most recent filing with the SEC. Institutional investors own 71.41% of the company’s stock.

Lunai Bioworks Company Profile

(Get Free Report)

Enochian Biosciences, Inc, a pre-clinical stage biotechnology company, engages in the research and development of pharmaceutical and biological products for the human treatment of human immunodeficiency virus (HIV), hepatitis B virus (HBV), influenza and coronavirus infections, and cancer. The company’s lead candidate includes ENOB-HV-01 for autologous HIV curative treatment; ENOB-HV-11, a preventative HIV vaccine; ENOB-HV-12, a therapeutic HIV vaccine; and ENOB-HB-01, a coopting HBV polymerase. Its pipeline development products comprise ENOB-DC-11 off the shelf DC vaccine for multiple solid tumors; and ENOB-DC-21, a non-specific vaccine for intraturmoral injection.